Last reviewed · How we verify
NCT06164639
Potential Biomarkers and Pathogenic Mechanism for Reflux Aspiration-induced Lung Injury.
trial testing aspiration in ARDS, Human in 28 participants. Enrolling by invitation.
28 November 2025
Quick facts
| Lead sponsor | Shanghai Zhongshan Hospital |
|---|---|
| Status | ENROLLING BY INVITATION |
| Study type | OBSERVATIONAL |
| Enrollment | 28 |
| Start date | 28 November 2023 |
| Primary completion | 28 November 2025 |
| Estimated completion | 28 November 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- aspiration
- bronchial alveolar fluid
- EIT V/Q test
- Nitric oxide inhalation
Conditions studied
- ARDS, Human — all drugs for ARDS, Human →
- Aspiration Pneumonia — all drugs for Aspiration Pneumonia →
Sponsor
Shanghai Zhongshan Hospital
Who can join
Adults 18 to 99, any sex, with ARDS, Human or Aspiration Pneumonia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
There is limited research on aspiration pneumonia-induced ARDS (Acute Respiratory Distress Syndrome), and currently there is a lack of studies on corresponding biomarkers and pathogenic mechanisms. We hypothesize that pH and amylase in BAL (Bronchoalveolar Lavage) may serve as candidate biomarkers for inhalation-induced ARDS. Furthermore, we use EIT analysis to explore the pathological mechanisms of ARDS induced by AP and evaluate the clinical value of NO in improving hypoxemia.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06164639
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for ARDS, Human
Currently open trials in the same condition.
- NCT07070362 — Digital Early Warning System for Acute Lung Injury in Liver Surgery · recruiting
- NCT06572280 — Non-invasive Phrenic Nerve Stimulation in ARDS Patient · NA · recruiting
- NCT06119516 — Transpulmonary Pressure - Guided Mechanical Ventilation in Morbidly Obese ARDS Patients: a Feasibility Study. · NA · recruiting
- NCT06321497 — Extracorporeal Carbon Dioxide Removal Using PrismaLung in Reducing Ventilator Induced Lung Injury · recruiting
- NCT06486259 — Regional Assessment of the Risk of Lung Injury in Ventilated Patients · recruiting
Other Shanghai Zhongshan Hospital trials
Trials by the same sponsor.
- NCT07353476 — Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC · Phase 2 · not yet recruiting
- NCT07508956 — Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric · Phase 3 · not yet recruiting
- NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting
- NCT07531368 — BBAP With CS Mapping Guidance · NA · not yet recruiting
- NCT07501104 — Neoadjuvant Pucotenlimab Combined With Lenvatinib and Temozolomide in Resectable Stage IIB/III Acral Melanoma · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06164639 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Zhongshan Hospital
- Last refreshed: 30 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06164639.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing